drugset / Trial / NCT02100527

Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris

NCT02100527

Phase 2 Withdrawn Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a 6 week study to characterize the safety, tolerability and effects of PF-05175157 administered for 6 weeks in subjects with moderate to severe acne vulgaris.

Timeline

Start
2014-04
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05175157 Small molecule 200 mg

Indications